SRC and breast carcinoma: Cell cycle profiling of breast cancer cell lines treated with a range of AZD0424 concentrations for 24 h revealed, at best, a modest G1‐arrest at concentrations > 1 μm (Fig. 1B) and which is in agreement with other SRC inhibitors such as saracatinib or dasatinib [38, 42].